Protamine Sulfate During Transcatheter Aortic Valve Implantation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT02974660
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT02974660
-
- Other papers using this trial's data
- Protamine sulfate during transcatheter aortic valve implantation (PS TAVI) - a single-center, single-blind, randomized placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Poland
- Registry status
- Completed
Technical summary
Registry record NCT02974660. Randomized; single masking; primary purpose prevention. Start 2016-12 (registry gives no type); primary completion 2020-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Protamine Sulfate During Transcatheter Aortic Valve Implantation
- Acronym
- PS TAVI
- Condition
- Aortic Valve Stenosis
- Intervention (Drug)
- Protamine sulfate
- Intervention (Drug)
- 0.9% NaCl
- Lead sponsor
- Medical University of Warsaw
Record details
- Record id
cardio:ct-nct02974660- Content hash
ccdcf97ece463dfd308efa39fd9f890d253649d9b44b8d274ef5c703e219f1f9